A Phase Ⅱa Study of the Safety, Tolerability and Efficacy of BD111 in Herpes Simplex Virus Type I Stromal Keratitis

NCTID	NCT06474442 (View at clinicaltrials.gov)
Description	This study aims to compare the clinical efficacy and safety of BD111 injection in combination with standard therapy vs. standard therapy in herpes simplex virus type I stromal keratitis (HSK), providing preliminary confirmation of the clinical effectiveness of BD111 in combination with standard therapy. (Show More)
Development Status	Active
Indication	Herpes Simplex Virus Type I Stromal Keratitis
Disease Ontology Term	DOID:0080158
Compound Name	BD111
Sponsor	Shanghai BDgene Co., Ltd.
Funder Type	Industry
Recruitment Status	Not yet recruiting
Enrollment Count	40
Results Posted	Not Available

No.of Trial Sites	1
Locations	China